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Abstract
Background: Acute kidney injury (AKI) has been associated with high morbidity and mortality rates among critically
ill children. Cystatin C is a protease inhibitor, and studies have shown that it is a promising marker for the early
diagnosis of AKI. Our goal in this study was to assess whether serum cystatin C could serve as an accurate marker
for the diagnosis of AKI.
Methods: This prospective study was undertaken in the pediatric intensive care unit at King Abdulaziz University
Hospital. Serum creatinine and serum cystatin C levels were both measured in patients on admission (0 h) and at 6,
12, and 24 h after admission. AKI was diagnosed according to the modified pRIFLE criteria. Receiver operating
characteristic (ROC) curve analysis was performed to assess the utility of serum cystatin C for diagnosing AKI.
Results: A total of 62 patients were enrolled in this study, and 32 were diagnosed with AKI according to the
modified pRIFLE criteria (51.4 %). The area under the ROC curve for serum cystatin indicated that it was a good
marker for the diagnosis of AKI at 0, 6, 12 and 24 h, with sensitivities of 78, 94, 94 and 83 %, respectively. However,
the specificities of serum cystatin C at 0, 6, 12, and 24 h were 57, 57, 60 and 50 %, respectively. The optimal cutoff
value was 0.645 mg/L. The area under the ROC for serum creatinine showed sensitivities of 50, 65.4, 69.2 and 57.7 %
and specificities of 67.7, 70, 60 and 70 % at 0, 6, 12 and 24 h, respectively. The optimal cutoff value for serum
creatinine was 30 μmol/l. Comparisons of ROC curves revealed that serum cystatin C was superior to serum
creatinine for the diagnosis of AKI at 12 h (p = 0.03), but no differences were detected at 0, 6 or 24 h.
Conclusion: Serum cystatin is a sensitive, but not a specific, marker for the diagnosis of AKI in critically ill children.
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Background
Acute kidney injury (AKI) is common among pediatric
patients who are admitted to intensive care units
(ICUs)/critical care units, and this condition has been
associated with high morbidity and mortality rates [1, 2].
The etiology of AKI varies from simple dehydration,
which is managed by volume repletion, to multifactorial
causes in critically ill children, and it can require renal
replacement therapy. Various clinical criteria have emerged
with the goal of diagnosing AKI and classifying it along a
spectrum according to severity, including the RIFLE [3],
AKI Network (AKIN) [4], and Kidney Disease Improving
Global Outcomes (KDIGO) criteria [5]. All of these criteria
depend heavily on the serum creatinine level and/or urine
output (UOP).
However, the use of the serum creatinine level has
many drawbacks, including variability according to age
and sex and dependence on muscle mass, making it un-
suitable for diagnosis of malnourished children. There is
also a delay between the occurrence of significant renal
damage and the increase in the serum creatinine level.
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Further, it is difficult to rely solely on measuring UOP
for AKI diagnosis because nephrotoxic medications and
interstitial kidney disease are associated with normal to
increased UOP. Many biological markers have emerged
with the goal of detecting AKI early, including cystatin C
[6], neutrophil gelatinase-associated lipocalin [7], kidney
injury molecule-1 [8], and interleukin-18 [9].
Cystatin C is 13-kDa cysteine protease inhibitor that is
produced by all nucleated cells at a constant rate. This
compound is freely filtered by the glomeruli and com-
pletely catabolized by the proximal tubules with no secre-
tion; thus, it is promising for use in glomerular filtration
rate (GFR) estimation [10, 11].
In pediatric clinical studies, cystatin C has shown a
high predictive value for diagnosis, and some studies
have even shown that it is superior to serum creatinine
in the early detection of AKI. Recently, cystatin C has
been shown to be a sensitive marker for early AKI diag-
nosis in children admitted to a pediatric intensive care
unit (PICU) [12]. Serum and urinary cystatin C have also
been shown to be good markers for AKI in heteroge-
neous pediatric populations, including patients from an
emergency department [13], a neonatal ICU [14], and a
post-cardiac surgery unit [15].
In this study, we aimed to assess the utility of serum
cystatin C for AKI diagnosis in children admitted to a
PICU.
Methods
This was a prospective study of children admitted to the
PICU at King Abdulaziz University Hospital, Jeddah,
Saudi Arabia from June to August, 2013.
Any sick patient ranging in age from over 1 month to
18 years of age who was admitted to the PICU was con-
sidered at risk of developing AKI and eligible for inclu-
sion in the study. They were screened for AKI by
performing serial measurements of serum creatinine
levels during the first 48 h after admission to assess
changes in the estimated GFR as well as in the serum
cystatin C level. The exclusion criteria included the
following: patients who were known to have chronic
kidney disease (CKD) at stage 3 to 5 (GFR < 60 mL/
1.73 m2/min); and patients who were stable clinically
and were admitted only for elective procedures, such
as central line insertion. Neonates were not included
because they are not allowed to be admitted to the
PICU as per hospital regulations.
Data collection
We collected demographic data, medical histories, rea-
sons for admission to the PICU, diagnoses, fluid balance
information, anthropometric measurements, laboratory
test results, and data on the need for renal replacement
therapy.
The modified pRIFLE criteria were used to diagnose
AKI according to the serum creatinine level and UOP at
the time of admission or during treatment at the PICU
[16]. The serum creatinine and serum cystatin C levels
were measured at the time of admission (zero time) and
at 6, 12 and 24 h after admission. Approximately 5 mL
of blood was obtained each time.
Laboratory tests
The serum creatinine level was measured using the Jaffe
kinetic spectrophotometric method, which is known for
its low specificity because many chromogenic substances
interfere with the accurate determination of the GFR
and calibration is difficult. The serum cystatin C level
was measured according to the manufacturer’s protocol
supplied with the ELISA kit, and the reference interval
was calculated nonparametrically and was determined to
be 0.53–0.95 mg/L. This range of values pertains to the
central 95 % of the population. In ELISA, turbidity and
particles in samples may interfere with measurements.
Therefore, samples containing particles were centrifuged
prior to performing this assay.
AKI analysis
The AKI patients were classified into three categories
(Risk, Injury, Failure) based on the magnitude of change
in the estimated GFR or in UOP as follows: risk stage,
25 % decrease in the GFR and UOP < 0.5 mL/kg/h for 8 h;
injury stage, 50 % decrease in the GFR and/or UOP <
0.5 mL/kg/h after 16 h; and failure stage, 75 % decrease in
the GFR or GFR < 35 mL/min/1.73 m2 and/or UOP <
0.3 mL/kg/h for 24 h or anuria for 12 h [16]. The baseline
creatinine level was defined as the last creatinine measure-
ment within the previous 6 months prior to PICU admis-
sion; for those patients who were admitted for the first
time with no previous creatinine measurement, we used
the average normal GFR according to the age and sex of
the child [17]. The estimated glomerular filtration rate
(eGFR) was calculated using the bedside Schwartz formula
[18], which utilizes the concentration of serum creatinine
(μmol/l), the height of the child (cm) and a constant to es-
timate the glomerular filtration rate:
eGFR ¼ k  Height
Serum Creatinine
Where k is a constant that depends on muscle mass,
which itself varies with a child’s age: For infants and
children aged 1 to 12 years, K = 0.55. For children above
12 years old, K for girls 0.55 and for boys 0.70 [18].
Statistical analysis
The following statistical analyses were performed using
IBM SPSS statistics version 20.0:
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1. The Shapiro-Wilk test was used to test the normality
of the study sample.
2. Descriptive statistics were used to calculate the
mean, standard deviation, median, quartiles.
3. The Chi-square test for association was used to
determine whether there was any relationship
between the categorical variables and AKI status.
4. Receiver operating characteristic (ROC) curves were
constructed to provide a natural common scale for
comparing different predictors that were measured
in different units and to interpret sensitivity and
specificity levels to determine the best cutoff value.
The Hanley method was used to compare the ROC
curves of serum cystatin C and serum creatinine.
5. The Mann-Whitney test was used to compare data
that were non-normally distributed.
Results
Demographic characteristics
A total of 62 patients, comprising 35 boys and 27 girls,
were recruited for the study.
The median age for AKI occurrence was 18 months,
with an interquartile range of 8 to 42 months, while for
non-AKI patients, the median age was 20.5 months, with
an interquartile range of 6 to 54 months. Age and gender
had no effect on the development of AKI. According to the
modified pRIFLE criteria, 32 patients had AKI (51.6 %),
and they were categorized as follows: Risk class, 18 patients
(56.3 %); Injury class, 10 patients (31.5 %); and Failure
class, 4 patients (12.5) based on modified pRIFLE criteria.
The most common cause of AKI was sepsis, which oc-
curred in 16 patients (50 %), followed by hypoxia, defined
as prolonged low oxygen saturation related to respiratory
or cardiac disease, which was found in 13 patients (39 %).
According to the pRIFLE criteria, only 4 patients were
diagnosed with AKI at the time of admission (0 time), 10
patients at 6 h, 6 patients at 12 h and 12 patients at 24 h.
A true baseline creatinine level was available for 28
patients (14 with AKI and 14 without AKI; measured
during the previous 6 months), and for the remaining
34 patients (18 with AKI and 16 without AKI), the GFR
was estimated using the Schwartz formula [17].
The Mann-Whitney test showed that baseline GFR
was not different between the non-AKI and AKI groups
The non-AKI mean rank was 32.87, and the AKI mean
rank was 30.22 (see Table 1).








Age (months) 18 (8–42) 20.5 (6–54) 0.05
Sex
Male 19 (59.3 %) 16 (53.3 %) 0.79
Female 13 (40.7 %) 14 (46.7 %)
RIFLE stage for AKI group
RIFLE 18 (56.3 %)
Injury 10 (31.25 %)
Failure 4 (12.5 %)
Possible etiologies for AKI group (N = 32)
Hypoxia/ischemia/ATN 13 (40.6 %)
Sepsis 16 (50.0 %)
Glomerulonephritis 2 (6.3 %)
Urinary tract obstruction 1 (3.1 %)
Nephrology consultation 13 (40.6 %)
Diuretic use 23 (71.8 %)
Renal replacement 1 (3.1 %)
Basal GFR (ml/min/1.73 m2) (median-interquartile range) 80 (66–96) 109 (79–124) 0.08
Basal creatinine (μmol/l) (median-interquartile range) 41.5 (31–51.2) 29.4 (24–34,4) 0.05
Basal cystatin C (mg/l) (median-interquartile range) 0.901.7 (0.802.5–1.502) 0.611.6 (0.549–0.672) 0.05
Mortality 4 (12.5 %) 1 (3.3 %) 0.114
Creatinine on discharge (μmol/l) (median-interquartile range) 28.0 (23–35) 28.72 (24–34.2) 0.832
GFR at discharge (ml/min/1.73 m2) (median-interquartile range) 102.5 (82.5–114.5) 104.7 (84–120) 0.535
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The estimated GFR on discharge was higher in the non-
AKI comparing to AKI groups The non-AKI mean rank
was 32.69, and the AKI mean rank was 24.00 (see Table 1).
Utility of serum cystatin C for diagnosing AKI
We performed ROC analysis at each time point to assess
the utility of serum cystatin C for diagnosing AKI. An
investigational analysis revealed that the best cutoff
values for serum cystatin C and serum creatinine were
0.645 mg/L and 30 μmol/l, respectively.
At 0 h, ROC curve analysis revealed that the area under
the curve (AUC) was 0.825 (95 % CI: 0.694–0.956), with a
sensitivity of 78 % and a specificity of 57 %. In compari-
son, serum creatinine at 0 h had a sensitivity of 50 %
and a specificity of 67.7 %, with an AUC of 0.733 (95 %
CI: 0.605–0.867). The ROC curves were not significantly
different (p = 0.26; see Fig. 1).
At 6 h, the AUC for serum cystatin C was 0.825 (95 %
CI: 0.694–0.956), with a sensitivity of 94 % and a specifi-
city of 57 %. In comparison, the area under the curve for
serum creatinine was 0.704, with a sensitivity of 65.4 %
and a specificity of 70 % (95 % CI: 0.567–0.841). This
difference was not significant (p = 0.15; see Fig. 2).
At 12 h, the AUC for serum cystatin C was 0.843
(95 % CI: 0.732–0.953), with a sensitivity of 94 % and a
specificity of 60 %. In comparison, the AUC for serum
creatinine was 0.658 (95 % CI: 0.510–0.805), with a
sensitivity of 69.2 % and a specificity of 60 %. This
difference was significant (p = 0.03; see Fig. 3).
Finally, at 24 h, the AUC for serum cystatin C was
0.780 (95 % CI: 0.634–0.925), with a sensitivity of 83 %
and a specificity of 50 %. In contrast, the AUC for serum
creatinine was 0.658 (95 % CI: 0.504–0.812), with a
sensitivity of 57.7 % and a specificity of 70 %. This
difference was not significant (p = 0.18; see Fig. 4).
We conclude that serum cystatin C has a good sensi-
tivity but lacks specificity for the diagnosis of AKI during
the first 24 h after ICU admission. The diagnostic ability
of serum cystatin C was superior to that of serum
creatinine at 12 h, but no differences were detected
at 0 h, 24 h or 48 h.
Discussion
In our cohort, 51.6 % of the admitted patients were diag-
nosed with AKI. This incidence is similar to those ob-
served in other pediatric cohorts [2, 15], indicating that
AKI is a significant and common issue among critically
ill children.
The mortality rate is high among children admitted to
ICUs who are diagnosed with AKI, with reported rates
ranging from 40 to 46 % [19–21]. A study conducted in
Poland showed that AKI is associated with a 4.4 times
higher risk of death compared with the total mortality
rate for PICU patients [22]. Another study conducted in
Fig. 1 ROC analysis of cysatatin C at 0 h for the diagnosis of AKI had a sensitivity of 78 % and a specificity of 57 % with a cutoff 0.645, while
serum creatinine had a sensitivity of 50 % and a specificity of 67.7 % with a cutoff value of 30 umol/l
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Fig. 2 At 6 h, ROC analysis of serum cystatin C revealed a sensitivity of 94 % and a specificity of 57 % with cut-off value of 0.645 mg/l, while ROC analysis
of serum creatinine showed a sensitivity of 65.4 % and a specificity of 70 % with cut-off value of 30 umol/l. This difference was not significant (p= 0.15)
Fig. 3 At 12 h, ROC analysis of serum cystatin C revealed a sensitivity of 94 % and a specificity of 60 % with cut-off value of 0.645 mg/l, while ROC analysis
of serum creatinine showed a sensitivity of 69.2 % and a specificity of 60 % with cut-off value of 30 umol/l. This difference was significant (p= 0.03)
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Canada has reported that AKI is an independent risk
factor for mortality, a longer length of hospital stay and
prolonged mechanical ventilation in critically ill children
[23]. Similarly, we have reported that hypervolemia,
mechanical ventilation, RIFLE class failure and renal re-
placement therapy initiation are associated with a higher
likelihood of death for AKI patients in a PICU [20].
We used only the pRIFLE definition of AKI in this
study and did not consider the other definitions of AKIN
and KDIGO because Sutherland SM et al. have recently
shown that all three definitions are equally excellent and
provide good discrimination in children [24].
We found that early measurement of the serum cysta-
tin C level within first 24 h is a sensitive predictor of
AKI in critically ill children. This finding is similar to
those of other cohort studies of children admitted to
ICUs. Herrero-Morin et al. have shown that the serum
cystatin C and beta-2 microglobulin levels are more
strongly correlated with creatinine clearance than with
serum creatinine in children with AKI admitted to an
ICU [25]. Another study conducted in Iran has reported
that the sensitivity and specificity of serum cystatin C
for diagnosing AKI are 73.9 % and 78.9, respectively,
using 0.6 mg/ml as the cutoff value [12]. Similarly, a
study conducted by Lagos-Arevaldo et al. of 160 non-
cardiac patients admitted to a PICU has reported that
serum cystatin C has more diagnostic accuracy than
serum creatinine and a greater predictive value for clinical
outcomes [26].
Serum cystatin C has also been reported to have a
higher predictive value for early AKI diagnosis in children
who have undergone cardiac surgery. In a study of 100
children who underwent cardiopulmonary bypass, Has-
singer et al. showed that serum cystatin C is highly sensi-
tive and predictive in diagnosing AKI, with an AUC of the
ROC curve of 0.834–0.875 [27]. Similarly, Krawczeski
et al. conducted a study of 347 children showing that
serum cystatin C is an early predictive biomarker for
AKI and clinical outcome after pediatric cardiopulmonary
bypass [15].
In our cohort, we did not include the neonatal age
group, which could have biased our results. As previ-
ously stated, we did not include neonates because the
hospital policy does not allow for admission of babies
<28 days of age to the PICU. However, serum cystatin C
has been demonstrated to be sensitive marker for AKI
diagnosis in asphyxiated babies [14].
Other studies have shown contradictory results and
have found that cystatin C is a poor marker for AKI
diagnosis. A recent study of 32 pediatric patients admit-
ted to an ICU demonstrated that the use of serum cysta-
tin C is not superior to that of serum creatinine for the
Fig. 4 At 24 h, ROC analysis of serum cystatin C revealed a sensitivity of 83 % and a specificity of 50 % with cut-off value of 0.645 mg/l, while
ROC analysis of serum creatinine showed a sensitivity of 57.7 % and a specificity of 70 % with cut-off value of 30 umol/l. This difference was not
significant (p = 0.18)
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diagnosis of AKI [28]. This finding is similar to that of a
clinical study performed by Royakkers et al., who dem-
onstrated that both serum and urine cystatin C are poor
markers for the diagnosis of AKI and that they do not
predict the need for renal replacement therapy [29].
There is no clear explanation for these conflicting re-
sults, but they might reflect the heterogeneity of the
populations assessed and differences in the AKI defini-
tions used; another possibility is that different cutoff
values for serum creatinine were used to diagnose AKI
in these studies.
We found that serum cystatin C lacked specificity for
the diagnosis of AKI. This finding could be explained by
the observation that the serum cystatin C level can be af-
fected by factors such as hyper/hypothyroidism [30], ster-
oid treatment [31], growth hormone [32], and insulin [33].
Despite the utility of serum cystatin C for the early
diagnosis of AKI, it is not clear whether it has any im-
pact on or role in the management of this condition.
AKI management currently involves supportive manage-
ment and renal replacement therapy if needed. With the
exception of immunosuppressive medication administra-
tion to patients with an immune-mediated disease, no
pharmaceutical management strategy has been found to
improve the outcome of AKI. In a randomized con-
trolled trial, Ricci et al. showed that fenoldopam infusion
in children with congenital heart disease who were
undergoing cardiopulmonary bypass decreased the levels
of urinary cystatin C and NGAL at the end of surgery
and at 12 h after surgery [34]. The incidence of AKI
was lower in the fenoldopam group (50 %) compared
with the placebo group (72 %); however, this difference
was not significant. Thus, further prospective studies are
required to establish a link between cystatin C and inter-
ventional therapy that can prevent or halt the progression
of AKI and to assess the role of cystatin C in improving
patient outcomes.
Another potential source of bias is that we only in-
cluded patients who had been admitted to the PICU and
did not include those who came to the emergency de-
partment and are at risk of community-acquired AKI.
However serum cystatin C has been reported to be a
good marker for AKI diagnosis in patients presenting at
an emergency department [13].
The tests for both the serum creatinine and serum
cystatin C levels are automated, and the labor costs are
minimal. However, the cost of measuring the serum
cystatin C level is more than that of measuring the
serum creatinine level because of the higher cost of re-
agents. The cost of cystatin C reagents is $4 per test,
which is 20 times the cost of the creatinine test using
the Jaffé reaction ($0.20) and about 3 times the cost of
enzymatic creatinine assay. However, this extra cost of
the cystatin C test should not preclude its use [35].
Conclusions
To our knowledge, this is the first study conducted in
Saudi Arabia to assess the utility of serum cystatin C for
the early diagnosis of AKI. Our study has several limita-
tions, including the following: 1) it was a single-center
study with a relatively small number of patients; 2) the
definition of AKI used in this study was based on changes
in the eGFR according to the Schwartz formula and using
serum creatinine, which has several drawbacks, as previ-
ously mentioned, and might have compromised the accur-
acy of serum cystatin C for the detection of AKI. 3) We
lack data regarding other factors that could affect levels of
serum cystatin C, such as steroid therapy, the use of insu-
lin and thyroid function test results.
We believe that further prospective studies are needed
with evaluation of several multicenter studies, which will
increase the sample size. In addition, a prolonged
follow-up period is needed to assess the long-term out-
comes of AKI and to evaluate the possible role of cysta-
tin in the prediction of long-term outcome.
AKI is common in critically ill children.
Serum cystatin C is a sensitive marker for diagnosis of
AKI in critically ill children if it is measured within the
first 24 h of admission.
Serum cystatin C lacks specificity for AKI diagnosis in
patients admitted to the PICU.
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